Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System.
Demers AM, Venter A, Friedrich SO, Rojas-Ponce G, Mapamba D, Jugheli L, Sasamalo M, Almeida D, Dorasamy A, Jentsch U, Gibson M, Everitt D, Eisenach KD, Diacon AH. Demers AM, et al. Among authors: jugheli l. J Clin Microbiol. 2016 May;54(5):1276-81. doi: 10.1128/JCM.03162-15. Epub 2016 Feb 24. J Clin Microbiol. 2016. PMID: 26912751 Free PMC article. Clinical Trial.
Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity.
Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, Heinrich N, Hoelscher M, Diacon AH; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics. Kayigire XA, et al. J Clin Microbiol. 2013 Jun;51(6):1894-8. doi: 10.1128/JCM.03290-12. Epub 2013 Apr 17. J Clin Microbiol. 2013. PMID: 23596237 Free PMC article.
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.
Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Friedrich SO, et al. Lancet Respir Med. 2013 Aug;1(6):462-70. doi: 10.1016/S2213-2600(13)70119-X. Epub 2013 Jul 1. Lancet Respir Med. 2013. PMID: 24429244 Free article. Clinical Trial.
The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.
Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics. Honeyborne I, et al. J Clin Microbiol. 2014 Aug;52(8):3064-7. doi: 10.1128/JCM.01128-14. Epub 2014 May 28. J Clin Microbiol. 2014. PMID: 24871215 Free PMC article.
Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study.
Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya NE, Mfinanga E, Said K, Haraka F, Rachow A, Saathoff E, Mpina M, Jugheli L, Lwilla F, Marais BJ, Hoelscher M, Daubenberger C, Reither K, Geldmacher C. Portevin D, et al. Among authors: jugheli l. Lancet Infect Dis. 2014 Oct;14(10):931-8. doi: 10.1016/S1473-3099(14)70884-9. Epub 2014 Aug 31. Lancet Infect Dis. 2014. PMID: 25185458
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH; Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA); Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA. Heinrich N, et al. J Antimicrob Chemother. 2015 May;70(5):1558-66. doi: 10.1093/jac/dku553. Epub 2015 Jan 27. J Antimicrob Chemother. 2015. PMID: 25630641 Clinical Trial.
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium. Aarnoutse RE, et al. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28827417 Free PMC article. Clinical Trial.
31 results